ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.732,79
0,27%
S&P 500
5.307,01
-0,27%
Dow Jones
39.671,04
0,00%
Euro vs US Dollar
1,08482
0,21%
Bitcoin
69.915,03
1,18%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Castle Biosciences Inc (CSTL)

  7. Castle Biosciences Inc (CSTL) News

CSTL

Castle Biosciences (CSTL)

Castle Biosciences Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:CSTL
DatumZeitQuelleÜberschriftSymbolFirma
15/05/202413h00Business WireCastle Biosciences to Present at the Leerink Partners Healthcare Crossroads ConferenceNASDAQ:CSTLCastle Biosciences Inc
14/05/202413h00Business WireCastle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett’s Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024NASDAQ:CSTLCastle Biosciences Inc
10/05/202421h14Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CSTLCastle Biosciences Inc
10/05/202413h00Business WireCastle Biosciences’ IDgenetix® Test Receives 2024 MedTech Breakthrough Award for “Best Overall Mental Health Solution”NASDAQ:CSTLCastle Biosciences Inc
08/05/202422h30Business WireLargest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class ResultNASDAQ:CSTLCastle Biosciences Inc
03/05/202413h00Business WireDecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and NeckNASDAQ:CSTLCastle Biosciences Inc
02/05/202422h05Business WireCastle Biosciences Reports First Quarter 2024 ResultsNASDAQ:CSTLCastle Biosciences Inc
30/04/202422h30Business WireCastle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood’s Designation as a Sun Safe Leadership Model City by IMPACT MelanomaNASDAQ:CSTLCastle Biosciences Inc
11/04/202413h00Business WireCastle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024NASDAQ:CSTLCastle Biosciences Inc
10/04/202423h00Business WireCastle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational CollaborationsNASDAQ:CSTLCastle Biosciences Inc
10/04/202413h00Business WireCastle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive YearNASDAQ:CSTLCastle Biosciences Inc
04/04/202422h30Business WirePresentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin CancerNASDAQ:CSTLCastle Biosciences Inc
02/04/202413h00Business WireCastle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:CSTLCastle Biosciences Inc
27/03/202422h00Business WireCastle Biosciences Announces Updates to its Board of DirectorsNASDAQ:CSTLCastle Biosciences Inc
25/03/202412h00Business WireCastle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive YearNASDAQ:CSTLCastle Biosciences Inc
22/03/202421h30Business WireLong-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNBNASDAQ:CSTLCastle Biosciences Inc
19/03/202412h00Business WireLeading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation TherapyNASDAQ:CSTLCastle Biosciences Inc
15/03/202421h30Business WireNew Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and OlderNASDAQ:CSTLCastle Biosciences Inc
12/03/202412h00Business WireCastle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor ForumNASDAQ:CSTLCastle Biosciences Inc
08/03/202422h30Business WireCastle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual MeetingNASDAQ:CSTLCastle Biosciences Inc
07/03/202413h00Business WireIn Novel Cohort, New Data Confirms DecisionDx®-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk SubgroupsNASDAQ:CSTLCastle Biosciences Inc
07/03/202400h07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CSTLCastle Biosciences Inc
07/03/202400h04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CSTLCastle Biosciences Inc
07/03/202400h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CSTLCastle Biosciences Inc
28/02/202423h15Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CSTLCastle Biosciences Inc
28/02/202422h05Business WireCastle Biosciences Reports Fourth Quarter and Full-Year 2023 ResultsNASDAQ:CSTLCastle Biosciences Inc
26/02/202413h00Business WireStudy Finds DecisionDx®-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition StagingNASDAQ:CSTLCastle Biosciences Inc
07/02/202413h00Business WireCastle Biosciences to Release Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call on Wednesday, Feb. 28, 2024NASDAQ:CSTLCastle Biosciences Inc
18/01/202413h00Business WireNew Study Highlights Significant Potential Medicare Savings Through Use of Castle Biosciences’ DecisionDx®-SCC Test to Guide Adjuvant Radiation Therapy Decisions in Patients with Cutaneous Squamous Cell CarcinomaNASDAQ:CSTLCastle Biosciences Inc
14/01/202410h30Business WireCastle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii®NASDAQ:CSTLCastle Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:CSTL

Kürzlich von Ihnen besucht

DBI
I1HP
IN XTK MSCI WLD ENERGY SF
TSX
TUEX
TD Active US Enhanced Di...
NYSE
PVR
Penn Virginia Res
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten